Mouse guanylate‐binding protein 1 does not mediate antiviral activity against influenza virus in vitro or in vivo
Immunology & Cell Biology · 2023
DOI: 10.1111/imcb.12627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology & Cell Biology, 2023. Verfasst von Melkamu B Tessema und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Influenza, Human, GTP-Binding Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Many interferon (IFN)‐stimulated genes are upregulated within host cells following infection with influenza and other viruses. While the antiviral activity of some IFN‐stimulated genes, such as the IFN‐inducible GTPase myxoma resistance (Mx)1 protein 1, has been well defined, less is known regarding the antiviral activities of related IFN‐inducible GTPases of the guanylate‐binding protein (GBP) family, particularly mouse GBPs, where mouse models can be used to assess their antiviral properties in vivo . Herein, we demonstrate that mouse GBP1 (mGBP1) was upregulated in a mouse airway epithelial cell line (LA‐4 cells) following pretreatment with mouse IFNα or infection by influenza A virus (IAV). Whereas doxycycline‐inducible expression of mouse Mx1 (mMx1) in LA‐4 cells resulted in reduced susceptibility to IAV infection and reduced viral growth, inducible mGBP1 did not. Moreover, primary cells isolated from mGBP1‐deficient mice (mGBP1 −/− ) showed no difference in susceptibility to IAV and mGBP1 −/− macrophages showed no defect in IAV‐induced NLRP3 (NLR family pyrin domain containing 3) inflammasome activation. After intranasal IAV infection, mGBP1 −/− mice also showed no differences in virus replication or induction of inflammatory responses in the airways during infection. Thus, using complementary approaches such as mGBP1 overexpression, cells from mGBP1 −/− mice and intranasal infection of mGBP1 −/− we demonstrate that mGBP1 does not play a major role in modulating IAV infection in vitro or in vivo .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
- Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
- WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
ORCID-Profile: Melkamu B Tessema
Förderung
- National Health and Medical Research Council
Zitieren
APA
Tessema, M. B., Tuipulotu, D. E., Oates, C. V., Brooks, A. G., Man, S. M., Londrigan, S. L., & Reading, P. C. (2023). Mouse guanylate‐binding protein 1 does not mediate antiviral activity against influenza virus in vitro or in vivo. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12627
Vancouver
Tessema MB, Tuipulotu DE, Oates CV, Brooks AG, Man SM, Londrigan SL, et al. Mouse guanylate‐binding protein 1 does not mediate antiviral activity against influenza virus in vitro or in vivo. Immunology & Cell Biology. 2023. doi:10.1111/imcb.12627
BibTeX
@article{Tessema2023,
author = {Tessema, Melkamu B and Tuipulotu, Daniel Enosi and Oates, Clare V and Brooks, Andrew G and Man, Si Ming and Londrigan, Sarah L and Reading, Patrick C},
title = {Mouse guanylate‐binding protein 1 does not mediate antiviral activity against influenza virus in vitro or in vivo},
journal = {Immunology & Cell Biology},
year = {2023},
doi = {10.1111/imcb.12627}
}
EUVIMED